Inspire(US:INSP) Globenewswire·2025-11-17 13:08Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit claims are based on Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in Inspire stock. The case is currently pending in the U.S. District Court for the District of Minnesota [3]. Stock Performance - On August 4, 2025, Inspire announced that the launch of Inspire V would face an "elongated timeframe," leading to a reduction in its 2025 earnings per share guidance by over 80%. This announcement was attributed to undisclosed factors affecting the rollout and weak demand due to excess inventory of older devices [7][8]. Impact of News - Following the announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].